News & Updates
Filter by Specialty:
SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong
A cost minimization analysis based on a literature review and Hong Kong data suggests that using subcutaneous (CS) instead of intravenous (IV) trastuzumab for HER2-positive breast cancer (BC) patients can offer an annual saving of more than USD 8.3 million to the Hong Kong healthcare system.
SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong
20 Mar 2023Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
Genetic susceptibility to ovarian cancer does not appear to modify the protective association between frequent aspirin use and the risk of developing the cancer, as shown in a study.
Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
19 Mar 2023Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.
Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
15 Mar 2023TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas
Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.
TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas
15 Mar 2023NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.
NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
15 Mar 2023Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023Garlic vegetable intake prevents gastric cancer
Greater dietary intake of allium vegetables, particularly garlic, provides a protective benefit against the development of gastric cancer (GC), suggests a study. This association is independent from vitamin or garlic supplementation.